MXPA01011070A - Derivados de esteroides. - Google Patents

Derivados de esteroides.

Info

Publication number
MXPA01011070A
MXPA01011070A MXPA01011070A MXPA01011070A MXPA01011070A MX PA01011070 A MXPA01011070 A MX PA01011070A MX PA01011070 A MXPA01011070 A MX PA01011070A MX PA01011070 A MXPA01011070 A MX PA01011070A MX PA01011070 A MXPA01011070 A MX PA01011070A
Authority
MX
Mexico
Prior art keywords
steroid derivatives
steroid
derivatives
Prior art date
Application number
MXPA01011070A
Other languages
English (en)
Inventor
Shutsung Liao
Original Assignee
Arch Dev Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arch Dev Corp filed Critical Arch Dev Corp
Publication of MXPA01011070A publication Critical patent/MXPA01011070A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MXPA01011070A 1999-04-30 2000-04-27 Derivados de esteroides. MXPA01011070A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13172899P 1999-04-30 1999-04-30
US19186400P 2000-03-24 2000-03-24
PCT/US2000/011243 WO2000066611A1 (en) 1999-04-30 2000-04-27 Steroid derivatives

Publications (1)

Publication Number Publication Date
MXPA01011070A true MXPA01011070A (es) 2003-06-30

Family

ID=26829742

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01011070A MXPA01011070A (es) 1999-04-30 2000-04-27 Derivados de esteroides.

Country Status (13)

Country Link
US (2) US6645955B1 (es)
EP (1) EP1189922A4 (es)
JP (1) JP2002543216A (es)
KR (1) KR20020028876A (es)
CN (1) CN1187364C (es)
AU (1) AU775630B2 (es)
BR (1) BR0010197A (es)
CA (1) CA2372493A1 (es)
IL (1) IL146223A0 (es)
MX (1) MXPA01011070A (es)
NO (1) NO20015314L (es)
NZ (1) NZ515810A (es)
WO (1) WO2000066611A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002211563A1 (en) * 2000-10-06 2002-04-15 Aeson Therapeutics Inc. Compounds useful for treating hypertriglyceridemia
US20020116731A1 (en) * 2000-12-11 2002-08-22 Allen Keith D. Transgenic mice containing retinoid X receptor interacting protein gene disruptions
GB0101933D0 (en) * 2001-01-25 2001-03-07 Astrazeneca Ab Therapy
CA2438221A1 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
US7078396B2 (en) 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
CA2446314C (en) * 2001-05-03 2011-02-22 The University Of Chicago Liver x receptor agonists
US20070197484A1 (en) * 2001-05-03 2007-08-23 Ching Song Method of treating disorder related to high cholesterol concentration
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
US6924311B2 (en) 2001-10-17 2005-08-02 X-Ceptor Therapeutics, Inc. Methods for affecting various diseases utilizing LXR compounds
DE10154221A1 (de) * 2001-11-07 2003-05-15 Max Delbrueck Centrum Mittel zur Behandlung von Läsionen des Nervensystems
TW200300078A (en) * 2001-11-08 2003-05-16 Univ Chicago Method of treating disorder related to high cholesterol concentration
US20050171084A1 (en) * 2002-03-27 2005-08-04 Cairns William J. Methods of treatment with lxr modulators
CA2482195A1 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists
AU2003259188B2 (en) * 2002-07-19 2008-03-06 Aryx Therapeutics, Inc. Materials and methods for treating hypercholesterolemia
ATE496893T1 (de) 2002-12-20 2011-02-15 X Ceptor Therapeutics Inc Isochinolinonderivate und deren verwendung als medikamente
GB0304927D0 (en) 2003-03-04 2003-04-09 Resolution Chemicals Ltd Process for the production of tibolone
WO2005101011A2 (en) * 2004-04-15 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with lxr-alpha (lxra)
JP2008503547A (ja) * 2004-06-24 2008-02-07 ガラパゴス・ナムローゼ・フェンノートシャップ 骨ホメオスタシスを促進させる方法及び組成物
US20070032464A1 (en) * 2004-10-08 2007-02-08 Shutsung Liao Methods of treating cancers
WO2006047022A1 (en) 2004-10-25 2006-05-04 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of cholesterol homeostasis, for therapy of hypercholesterolemia, hyperlipidemia, and atherosclerosis
US8399441B2 (en) 2004-10-25 2013-03-19 Virginia Commonwealth University Nuclear sulfated oxysterol, potent regulator of lipid homeostasis, for therapy of hypercholesterolemia, hypertriglycerides, fatty liver diseases, and atherosclerosis
BRPI0518229A (pt) * 2004-10-27 2008-11-04 Daiichi Sankyo Co Ltd composto de benzeno tendo 2 ou mais substituintes
WO2006071451A2 (en) * 2004-12-03 2006-07-06 The Regents Of The University Of California Compounds that prevent macrophage apoptosis and uses thereof
JP2007035169A (ja) * 2005-07-27 2007-02-08 Matsushita Electric Ind Co Ltd 半導体記憶装置
WO2007140253A2 (en) * 2006-05-26 2007-12-06 Temple University - Of The Commonwealth System Of Higher Education Treatment of hiv-1 by modulation of vpr activation of the m-csf promoter
EP2457567B1 (en) 2007-09-19 2015-12-30 Nagoya Industrial Science Research Institute Agent having neurotrophic factor-like activity
WO2009059239A2 (en) * 2007-11-02 2009-05-07 Mayo Foundation For Medical Education And Research REDUCING Aβ42 LEVELS AND Aβ AGGREGATION
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
CN101514222B (zh) * 2009-04-09 2011-08-03 中国人民解放军第二军医大学 总合草苔虫中一种甾体类化合物及其用途
US8829213B2 (en) 2009-07-29 2014-09-09 The University Of Chicago Liver X receptor agonists
CN102071246A (zh) * 2009-08-27 2011-05-25 北京科技大学 新型中药制剂的开发与评价
EP2615094A4 (en) 2010-09-07 2013-09-18 Snu R&Db Foundation SESTERTERPEN COMPOUNDS AND THEIR USE
US9034859B2 (en) 2011-04-06 2015-05-19 Virginia Commonwealth University Sulfated oxysterol and oxysterol sulfation by hydroxysterol sulfotransferase promote lipid homeostasis and liver proliferation
CN106083976B (zh) * 2012-04-12 2018-02-09 弗吉尼亚联邦大学 用于治疗代谢障碍、高脂血症、糖尿病、脂肪肝疾病和动脉粥样硬化的新的胆固醇代谢物5‑胆甾烯‑3β,25‑二醇二硫酸酯(25HCDS)
CN103570790B (zh) * 2012-08-07 2016-06-01 中国科学院上海药物研究所 原人参二醇衍生物及其制备方法、包含该衍生物的组合物及其用途
SI3086793T1 (sl) 2013-12-24 2022-10-28 Virginia Commonwealth University Uporaba oksigeniranih holesterol sulfatov (OCS) za zdravljenje ledvične disfunkcije
MY180383A (en) 2013-12-24 2020-11-28 Harvard College Cortistatin analogues and syntheses and uses thereof
CA2939120A1 (en) 2014-01-10 2015-07-16 Rgenix, Inc. Lxr agonists and uses thereof
CN103694299A (zh) * 2014-01-13 2014-04-02 中国药科大学 甾体类雄激素受体抑制剂、其制备方法及其医药用途
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
CA3010883A1 (en) 2016-01-11 2017-07-20 The Rockefeller University Methods for the treatment of myeloid derived suppressor cells related disorders
CN105963307B (zh) * 2016-05-06 2019-08-09 深圳以诺生物制药有限公司 一种罗汉果醇衍生物单体及其组合物的用途
IT201600068742A1 (it) * 2016-07-01 2018-01-01 Bar Pharmaceuticals Soc A Responsabilita Limitata Derivati dell'acido iodesossicolico e loro uso
JP2019524772A (ja) 2016-08-02 2019-09-05 ヴァージニア コモンウェルス ユニバーシティ ５−コレステン−３，２５−ジオール，３−サルフェート（２５ｈｃ３ｓ）又は薬学的に許容される塩及び少なくとも１種の環状オリゴ糖を含む組成物
CN107669688B (zh) * 2017-10-26 2020-02-14 河南中医药大学 3β-乙酰氧基-7,25-甘遂二烯-24R-醇在脂异常与糖尿病综合防治中的应用
US11214536B2 (en) 2017-11-21 2022-01-04 Inspirna, Inc. Polymorphs and uses thereof
MX2022007164A (es) 2019-12-13 2022-09-12 Inspirna Inc Sales metálicas y usos de estas.
CN111087441B (zh) * 2020-01-08 2021-06-22 黑龙江中医药大学 核桃青皮中一种三萜化合物的制备方法和应用
CN111349134B (zh) * 2020-04-23 2021-08-20 黑龙江中医药大学 核桃青皮中一种达玛烷型三萜化合物的制备方法
KR20220004451A (ko) * 2020-07-03 2022-01-11 연세대학교 산학협력단 지방간 질환의 예방 또는 치료를 위한 약학적 조성물

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2698853A (en) 1951-08-11 1955-01-04 Monsanto Chemicals Oxidation of steroids
FR1482102A (fr) * 1966-03-31 1967-05-26 Centre Nat Rech Scient Nouveaux dérivés de stéroïdes et procédé de préparation
US3784598A (en) * 1972-01-20 1974-01-08 Ciba Geigy Corp Process for the conversion of a 3-hydroxy-5,6-oxido group of a steroid into a delta4-3-oxo group
US3963765A (en) * 1973-04-01 1976-06-15 Yehuda Mazur Preparation of derivatives of cholesterol
US3887545A (en) * 1973-11-12 1975-06-03 Hoffmann La Roche Synthesis of 1{60 -hydroxylated cholesterol derivatives
US4006172A (en) * 1976-04-26 1977-02-01 The Upjohn Company Process for 7-keto-Δ5 -steroids
US4125544A (en) 1977-06-09 1978-11-14 G. D. Searle 20/22/23/24-Oxa-7-oxocholesterols and esters thereof
US4193930A (en) 1977-08-29 1980-03-18 G. D. Searle & Co. 25-Alkyl-3β-hydroxycholest-5-en-7-ones and esters thereof
JPS563000A (en) 1979-06-20 1981-01-13 Green Cross Corp:The Water-soluble cholesterol derivative
US4351767A (en) * 1981-06-29 1982-09-28 Kaiser Emil T Synthesis of 24,25-dihydroxycholesterol
US4639420A (en) * 1984-11-21 1987-01-27 Schaffner Carl P Method for the immunoanalysis of cholesterol epoxides
IT1212141B (it) * 1987-06-03 1989-11-08 So Ri Far S R L Composizioni farmaceutiche per la prevenzione e terapia della calcolosi delle vie biliari e della dispepsia biliare.
WO1989003212A1 (en) * 1987-10-13 1989-04-20 Pfizer Inc. 3,5-dihydroxy-6,8-nonadienoic acids and derivatives as hypocholesterolemic agents
US5562910A (en) 1989-09-25 1996-10-08 University Of Utah Research Foundation Vaccine compositions and method for enhancing an immune response
US5424463A (en) 1990-08-29 1995-06-13 Humanetics Corporation Δ5-androstenes useful for promoting weight maintenance or weight loss and treatment process
JPH0749438B2 (ja) * 1990-10-31 1995-05-31 東京田辺製薬株式会社 タウリン抱合型胆汁酸の精製方法
IT1255241B (it) * 1992-07-22 1995-10-20 Simos Contos Derivato di acido biliare e suo uso in terapia
IT1255486B (it) * 1992-08-04 1995-11-06 Erregierre Ind Chim Processo per preparare gli acidi biliari coniugati con la taurina
US5482935A (en) * 1993-01-05 1996-01-09 American Home Product Corporation Anti-atherosclerotic use of 17 alpha-dihydroequilin
TW289757B (es) 1993-05-08 1996-11-01 Hoechst Ag
IT1270853B (it) 1993-05-20 1997-05-13 Sanofi Elf Procedimento per la preparazione di derivati taurocolanici
CN1055929C (zh) 1993-09-20 2000-08-30 中国科学院上海有机化学研究所 三氟甲基甾体化合物及其制备方法
IT1274000B (it) 1994-04-06 1997-07-14 Alfa Wassermann Spa Derivati di acidi biliari utili nella terapia della calcolosi biliare da colesterolo e nelle patologie indotte da colestasi
ES2149365T3 (es) 1994-05-19 2000-11-01 Merck & Co Inc Oxidacion de esteroides que contienen grupos alilicos.
US5583239A (en) * 1995-05-30 1996-12-10 Lehigh University Antimicrobial sterol conjugates
CA2278123A1 (en) * 1997-01-24 1998-07-30 Karen Hanley Use of fxr, ppar.alpha. and lxr.alpha. activators to restore barrier function, promote epidermal differentiation and inhibit proliferation
US6060465A (en) * 1997-02-06 2000-05-09 Miljkovic; Dusan Bile acids and their derivatives as glycoregulatory agents
AU2389100A (en) * 1998-12-23 2000-07-12 Glaxo Group Limited Assays for ligands for nuclear receptors
WO2000040965A1 (en) * 1999-01-07 2000-07-13 Tularik, Inc. Fxr receptor-mediated modulation of cholesterol metabolism
CA2438221A1 (en) * 2001-02-08 2002-08-15 The University Of Chicago Steroidal derivatives
CA2446314C (en) * 2001-05-03 2011-02-22 The University Of Chicago Liver x receptor agonists
US7078396B2 (en) * 2001-05-03 2006-07-18 Arch Development Corporation Method of treating disorder related to high cholesterol concentration
CA2482195A1 (en) * 2002-04-12 2003-10-23 The University Of Chicago Farnesoid x-activated receptor agonists

Also Published As

Publication number Publication date
JP2002543216A (ja) 2002-12-17
AU4667200A (en) 2000-11-17
IL146223A0 (en) 2002-07-25
NZ515810A (en) 2004-05-28
US6645955B1 (en) 2003-11-11
WO2000066611A1 (en) 2000-11-09
EP1189922A1 (en) 2002-03-27
CA2372493A1 (en) 2000-11-09
BR0010197A (pt) 2002-07-16
CN1187364C (zh) 2005-02-02
US20040152681A1 (en) 2004-08-05
AU775630B2 (en) 2004-08-05
CN1357003A (zh) 2002-07-03
EP1189922A4 (en) 2002-08-14
NO20015314D0 (no) 2001-10-30
KR20020028876A (ko) 2002-04-17
NO20015314L (no) 2001-12-27

Similar Documents

Publication Publication Date Title
MXPA01011070A (es) Derivados de esteroides.
ZA200000894B (en) 4-Phenyl-pyridine derivatives.
ZA200201055B (en) Amino-triazolopyridine derivatives.
HUP0201535A2 (en) 5-cyano-2-aminopyrimidine derivatives
GC0000183A (en) 3-Phenyl-pyridine derivatives
ZA200109595B (en) 13-methyl-erythromycin derivatives.
HK1046411A1 (en) 5-Phenyl-pyrimidine derivatives.
IL148837A0 (en) Isoxazolecarboxamide derivatives
ZA200107346B (en) Erythromycin derivatives.
GC0000191A (en) 4-Phenyl-pyrimidine derivatives
ZA200201276B (en) 3-Amino-2-phenyl-propane derivatives.
IL150132A0 (en) Cyclopenteneone derivatives
GB0026485D0 (en) ›-Carboline derivatives
GC0000256A (en) Ethanesulfonyl-piperidine derivatives
IL145949A0 (en) 1-trifluoromethyl-4-hydroxy-7-piperidinyl-aminomethylchroman derivatives
MXPA01011285A (es) Derivados de tio-oxindol.
ZA200201873B (en) Fluorene derivatives.
ZA993232B (en) Arylthiazolidinedione derivatives.
ZA200107632B (en) Thio-oxindole derivatives.
ZA200203703B (en) New Phenalkyloxy-phenyl derivatives.
IL146282A0 (en) Thio-oxindole derivatives
GB9907134D0 (en) Antimor napthylcombretastatin derivatives
HK1043987A1 (zh) 硫-羥吲衍生物